Development of Nanoparticle Adaptation Phenomena in Acinetobacter baumannii: Physiological Change and Defense Response.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
14 02 2023
Historique:
pubmed: 11 1 2023
medline: 17 2 2023
entrez: 10 1 2023
Statut: ppublish

Résumé

The present work describes the evolution of a resistance phenotype to a multitargeting antimicrobial agent, namely, silver nanoparticles (nanosilver; NAg), in the globally prevalent bacterial pathogen Acinetobacter baumannii. The Gram-negative bacterium has recently been listed as a critical priority pathogen requiring novel treatment options by the World Health Organization. Through prolonged exposure to the important antimicrobial nanoparticle, the bacterium developed mutations in genes that encode the protein subunits of organelle structures that are involved in cell-to-surface attachment as well as in a cell envelope capsular polysaccharide synthesis-related gene. These mutations are potentially correlated with stable physiological changes in the biofilm growth behavior and with an evident protective effect against oxidative stress, most likely as a feature of toxicity defense. We further report a different adaptation response of A. baumannii to the cationic form of silver (Ag

Identifiants

pubmed: 36625664
doi: 10.1128/spectrum.02857-22
pmc: PMC9927149
doi:

Substances chimiques

Anti-Bacterial Agents 0
Silver 3M4G523W1G

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0285722

Références

Front Microbiol. 2021 Apr 16;12:652863
pubmed: 33936010
J Clin Outcomes Manag. 2010 Aug;17(8):363-369
pubmed: 26966345
Cell. 2009 Dec 24;139(7):1366-75
pubmed: 20064380
Sci Rep. 2019 Aug 13;9(1):11745
pubmed: 31409877
J Bacteriol. 2002 Feb;184(4):1204-8
pubmed: 11807084
Microb Genom. 2019 Oct;5(10):
pubmed: 31599224
Biomed Res Int. 2016;2016:2475067
pubmed: 27274985
Chem Biol. 2010 May 28;17(5):421-33
pubmed: 20534341
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
PLoS One. 2017 Aug 3;12(8):e0181363
pubmed: 28771501
Small. 2013 Nov 11;9(21):3554-60
pubmed: 23625828
Appl Environ Microbiol. 2008 Apr;74(7):2171-8
pubmed: 18245232
Antimicrob Agents Chemother. 2006 Dec;50(12):4114-23
pubmed: 17000742
Front Cell Infect Microbiol. 2020 May 29;10:253
pubmed: 32547965
Clin Microbiol Infect. 1998 May;4(5):248-254
pubmed: 11864339
Antimicrob Agents Chemother. 1991 Sep;35(9):1824-8
pubmed: 1952852
J Bacteriol. 2004 Oct;186(19):6526-35
pubmed: 15375134
Front Microbiol. 2016 Nov 16;7:1831
pubmed: 27899918
Nanotechnology. 2005 Oct;16(10):2346-53
pubmed: 20818017
Microorganisms. 2020 Nov 24;8(12):
pubmed: 33255319
Nat Biotechnol. 2013 Feb;31(2):160-5
pubmed: 23292609
Nat Rev Microbiol. 2019 Jul;17(7):441-448
pubmed: 30980069
Microbiology (Reading). 2001 Dec;147(Pt 12):3393-402
pubmed: 11739772
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Biometals. 2013 Aug;26(4):609-21
pubmed: 23771576
Int J Nanomedicine. 2016 Aug 12;11:3789-800
pubmed: 27574420
J Bacteriol. 1948 Oct;56(4):379-85
pubmed: 16561584
ACS Nano. 2017 Apr 25;11(4):3438-3445
pubmed: 28339182
Front Microbiol. 2019 Jul 17;10:1601
pubmed: 31379771
Front Genet. 2015 Feb 17;6:42
pubmed: 25741363
Iran J Basic Med Sci. 2015 Jun;18(6):623-6
pubmed: 26221488
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752093
Science. 2016 Dec 16;354(6318):
pubmed: 27980159
Proc Natl Acad Sci U S A. 1977 Nov;74(11):4767-71
pubmed: 200930
J Nanobiotechnology. 2021 Sep 27;19(1):291
pubmed: 34579731
Antimicrob Resist Infect Control. 2020 Jul 6;9(1):101
pubmed: 32631451
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9696-9698
pubmed: 31061135
Nat Rev Microbiol. 2004 Feb;2(2):95-108
pubmed: 15040259
J Pharm Bioallied Sci. 2010 Oct;2(4):282-9
pubmed: 21180459
Biometals. 1994 Jan;7(1):49-56
pubmed: 8118173
Front Microbiol. 2017 Mar 21;8:459
pubmed: 28377755
Emerg Microbes Infect. 2020 Dec;9(1):1149-1159
pubmed: 32419626
Nanomaterials (Basel). 2018 Aug 31;8(9):
pubmed: 30200373
Nat Rev Microbiol. 2016 Apr;14(5):320-30
pubmed: 27080241
Emerg Infect Dis. 2002 Sep;8(9):881-90
pubmed: 12194761
ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5557-5568
pubmed: 31927911
Annu Rev Microbiol. 2000;54:49-79
pubmed: 11018124
Front Public Health. 2014 Sep 16;2:145
pubmed: 25279369
Biochemistry. 2005 Oct 4;44(39):13214-23
pubmed: 16185089
Nat Med. 1999 Feb;5(2):183-8
pubmed: 9930866
Nanoscale. 2020 Jan 28;12(4):2384-2392
pubmed: 31930233
J Mol Biol. 2006 Nov 17;364(1):68-79
pubmed: 17005198
Osong Public Health Res Perspect. 2011 Dec;2(3):164-70
pubmed: 24159468
Front Microbiol. 2015 Jun 10;6:587
pubmed: 26113845
J Clin Microbiol. 2003 Mar;41(3):1062-8
pubmed: 12624030
Mol Aspects Med. 2009 Feb-Apr;30(1-2):42-59
pubmed: 18601945
Pathog Dis. 2018 Dec 1;76(9):
pubmed: 30657912
Water Res. 2009 Mar;43(4):1027-32
pubmed: 19073336
J Appl Microbiol. 2012 May;112(5):841-52
pubmed: 22324439
Nanomedicine. 2016 Apr;12(3):789-799
pubmed: 26724539
Pathogens. 2020 Jan 15;9(1):
pubmed: 31952222
Burns. 2015 Mar;41(2):364-71
pubmed: 25145873
Nat Nanotechnol. 2018 Jan;13(1):65-71
pubmed: 29203912
PLoS One. 2018 Oct 16;13(10):e0205815
pubmed: 30325949
Biometals. 1993 Spring;6(1):55-9
pubmed: 8471825
Front Microbiol. 2018 Mar 23;9:539
pubmed: 29628916
Environ Sci Technol. 2011 Sep 1;45(17):7589-90; author reply 7593-5
pubmed: 21819100
Future Microbiol. 2009 Apr;4(3):273-8
pubmed: 19327114
Infect Drug Resist. 2019 Jul 08;12:1985-2001
pubmed: 31372006
Mol Aspects Med. 2009 Feb-Apr;30(1-2):1-12
pubmed: 18796312
Antimicrob Agents Chemother. 2004 Apr;48(4):1430-2
pubmed: 15047561
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Genome Biol. 2008 Apr 17;9(4):R74
pubmed: 18419807
Euro Surveill. 2018 Apr;23(16):
pubmed: 29692315
Nat Nanotechnol. 2021 Sep;16(9):996-1003
pubmed: 34155383
Int J Mol Sci. 2019 Jun 08;20(11):
pubmed: 31181755
FEMS Microbiol Rev. 2003 Jun;27(2-3):341-53
pubmed: 12829274
Antibiotics (Basel). 2020 Jan 19;9(1):
pubmed: 31963769
Microb Genom. 2022 Jan;8(1):
pubmed: 35014949
Virulence. 2012 May 1;3(3):243-50
pubmed: 22546906
Infect Drug Resist. 2018 Aug 21;11:1249-1260
pubmed: 30174448
J Antimicrob Chemother. 2002 Apr;49(4):697-8
pubmed: 11909848
Antimicrob Agents Chemother. 2014 Oct;58(10):5809-17
pubmed: 25049246
Drug Resist Updat. 2018 Nov;41:26-39
pubmed: 30472242
Nat Commun. 2015 Aug 06;6:7983
pubmed: 26246187
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
J Bacteriol. 2008 Mar;190(6):2065-74
pubmed: 18192383
Environ Sci Technol. 2011 Jan 1;45(1):283-7
pubmed: 21133412
Small. 2009 Mar;5(3):341-4
pubmed: 19152359

Auteurs

Oliver McNeilly (O)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.

Riti Mann (R)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.

Max Laurence Cummins (ML)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.
Australian Centre for Genomic Epidemiological Microbiology, University of Technology Sydney, Broadway, New South Wales, Australia.

Steven P Djordjevic (SP)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.
Australian Centre for Genomic Epidemiological Microbiology, University of Technology Sydney, Broadway, New South Wales, Australia.

Mehrad Hamidian (M)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.

Cindy Gunawan (C)

Australian Institute of Microbiology and Infection, University of Technology Sydney, Broadway, New South Wales, Australia.
School of Chemical Engineering, University of New South Wales, Sydney, New South Wales, Australia.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Classifications MeSH